Table 2.
Radiological response to sorafenib in the study.
| Item | miR122_H group (n = 294) | miR122_L group (n = 294) | P value |
|---|---|---|---|
| 12-week radiological response | |||
| Complete response (n, %) | 4 | 2 | ― |
| Partial response (n, %) | 12 | 3 | ― |
| Stable disease (n, %) | 67 | 52 | ― |
| Progressive disease (n, %) | 211 | 237 | ― |
| Intrahepatic (n, %) | 169 | 184 | ― |
| Extrahepatic (n, %) | 11 | 20 | ― |
| Both (n, %) | 31 | 33 | ― |
| Overall response (n, %)a | 16 (5.4) | 5 (1.7) | 0.015 |
| Disease control (n, %)a | 83 (28.2) | 57 (19.4) | 0.012 |
|
| |||
| 24-week radiological response | |||
| Complete response (n, %) | 1 | 0 | ― |
| Partial response (n, %) | 7 | 1 | ― |
| Stable disease (n, %) | 19 | 10 | ― |
| Progressive disease (n, %) | 267 | 283 | ― |
| Intrahepatic (n, %) | 213 | 225 | ― |
| Extrahepatic (n, %) | 13 | 17 | ― |
| Both (n, %) | 41 | 41 | ― |
| Overall response (n, %) | 8 (2.7) | 1 (0.3) | 0.019 |
| Disease control (n, %) | 27 (9.2) | 11 (3.7) | 0.007 |
a“Overall response” was the sum of “complete response” + “partial response,” and “disease control” was the sum of “complete response” + “partial response” + “stable disease.”